ClinicalTrials.gg
CompletedNCT03390283Updated Nov 21, 2023

A Survey of Parent/Caregiver Practices on the Storage, Use, and Disposal of Opioids in a Comprehensive Cancer Center

An observational study in Caregiver and Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2023-11-21.

Sponsored by M.D. Anderson Cancer Center · Observational

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
115
Sex
All
01

Study summary

This trial uses a survey to study parent and caregiver practices on the storage, use, and disposal of opioids in a comprehensive cancer center. It is not known if parents and/or caregivers are aware of the guidelines and recommendations for proper and safe disposal of opioids. This survey will help health care providers assess the needs and improve the safety of patients and their families from the potential dangers of misuse and abuse of prescription opioid medications.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the frequency of unsafe storage, use, and disposal of unused and currently used opioids by parents and/or caregivers of patients 18 years and younger at MD Anderson Cancer Center.

II. To explore potential association between other covariates with the unsafe storage, use, and disposal of opioids.

OUTLINE:

Participants complete online survey on an iPad over 20 minutes.

02

Conditions studied

  • Caregiver
  • Malignant Neoplasm

Browse trials for

03

In context

Neoplasms

9,610 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.

This study's enrollment of 115 is below the median of 202 across 1,742 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 3,044 studies on the registry; 578 are open to participants now.

Of its 608 completed or terminated interventional studies of FDA-regulated products, 407 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Parents/caregivers of a child (under 18) who has received an opioid prescription within the last 6 months

Eligibility criteria

Inclusion Criteria:

  • PARENTS/CAREGIVERS: Must be at least 18 years old (a. The child of the parents/caregivers must be 18 years old or younger; b. The child of the parents/caregivers must have received an opioid prescription within the last six months.)
  • PARENTS/CAREGIVERS: Must be able to understand, read, write, and speak English.
  • PARENTS/CAREGIVERS: Parent/caregiver must sign an informed consent.
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
115 participants (actual)

Groups and cohorts

  • Observational (Online survey)

    Participants complete online survey on an iPad over 20 minutes.

    Other: Survey Administration

Interventions

  • OtherSurvey Administration

    Complete online survey

06

What researchers measure

Primary outcomes

  1. Reported frequencies of unsafe storage of opioids

    The unsafe storage of opioids is defined as having opioids in the open where anyone can see it, in a medicine cabinet that is not locked, or hidden but not locked. Will estimate the proportion along with a 95% confidence interval. The distribution of the primary outcome by demographic information will be presented in cross tabulations. The association between the primary outcomes and demographic information/other behavior will be explored by Chi-Squared test or Fisher's exact test when appropriate. Logistic regression models may be employed to assess the effect of demographic factors on the unsafe storage of opioids. Other statistics methods may be used when appropriate.

    Time frame: Up to 2 years

  2. Reported frequencies of unsafe use of opioids

    This is defined as giving more opioid than prescribed to the child very frequently, frequently, occasionally, infrequently, or very infrequently. Will estimate the proportion along with a 95% confidence interval. The distribution of the primary outcome by demographic information will be presented in cross tabulations. The association between the primary outcomes and demographic information/other behavior will be explored by Chi-Squared test or Fisher's exact test when appropriate. Logistic regression models may be employed to assess the effect of demographic factors on the unsafe storage of opioids. Other statistics methods may be used when appropriate.

    Time frame: Up to 2 years

  3. Reported frequencies of unsafe disposal of opioids

    This is defined as throwing unused pills in the trash without any modification. Will estimate the proportion along with a 95% confidence interval. The distribution of the primary outcome by demographic information will be presented in cross tabulations. The association between the primary outcomes and demographic information/other behavior will be explored by Chi-Squared test or Fisher's exact test when appropriate. Logistic regression models may be employed to assess the effect of demographic factors on the unsafe storage of opioids. Other statistics methods may be used when appropriate.

    Time frame: Up to 2 years

Secondary outcomes

  1. Other covariates

    The association between unsafe storage, use and disposal and other variables including the presence of other children living in the home \[defined as answering Question 9 as having minor children (age \< 18 years) in the home\], a family history of misuse of prescription drugs, street drugs or alcohol, a family history of psychiatric illness or other unsafe uses of opioid medications that do not relate directly to the child, such as if a caregiver takes or sells the child's medication will be analyzed. Demographic variables collected in the first part of the survey will be used to explore possible associations with unsafe storage, use or disposal of opioids.

    Time frame: Up to 2 years

07

Study locations

1 site
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Nov 2023, 70 months.

Of 792 non-industry observational studies under Neoplasms, half reached primary completion within 102 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 352. This study's 70 months is below that.

Counting every sponsor, half of 884 studies reached it within 80 months; a quarter within 32 and three quarters within 318.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2017
First posted
Jan 4, 2018
StartActual
Dec 20, 2017
Primary completionActual
Nov 17, 2023
CompletionActual
Nov 17, 2023
Last update
Nov 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03390283
Responsible party
Sponsor
First posted
Jan 4, 2018
Start date
Dec 20, 2017
Primary completion
Nov 17, 2023
Completion
Nov 17, 2023
Last update
Nov 21, 2023

Study contacts

Kevin Madden
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion